PL2056807T3 - Leczenie chorób zakaźnych - Google Patents

Leczenie chorób zakaźnych

Info

Publication number
PL2056807T3
PL2056807T3 PL07837041T PL07837041T PL2056807T3 PL 2056807 T3 PL2056807 T3 PL 2056807T3 PL 07837041 T PL07837041 T PL 07837041T PL 07837041 T PL07837041 T PL 07837041T PL 2056807 T3 PL2056807 T3 PL 2056807T3
Authority
PL
Poland
Prior art keywords
treatment
inflammatory diseases
inflammatory
diseases
Prior art date
Application number
PL07837041T
Other languages
English (en)
Inventor
Betty C Soliven
Original Assignee
Univ Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Chicago filed Critical Univ Chicago
Publication of PL2056807T3 publication Critical patent/PL2056807T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL07837041T 2006-08-17 2007-08-17 Leczenie chorób zakaźnych PL2056807T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83822206P 2006-08-17 2006-08-17
EP07837041A EP2056807B1 (en) 2006-08-17 2007-08-17 Treatment of inflammatory diseases
PCT/US2007/018331 WO2008021532A2 (en) 2006-08-17 2007-08-17 Treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
PL2056807T3 true PL2056807T3 (pl) 2013-02-28

Family

ID=38941849

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07837041T PL2056807T3 (pl) 2006-08-17 2007-08-17 Leczenie chorób zakaźnych

Country Status (16)

Country Link
US (3) US8258150B2 (pl)
EP (2) EP2056807B1 (pl)
JP (3) JP5216769B2 (pl)
CN (2) CN102526736B (pl)
AU (1) AU2007284337B2 (pl)
BR (1) BRPI0715950A2 (pl)
CA (1) CA2660880C (pl)
DK (1) DK2056807T3 (pl)
ES (1) ES2393631T3 (pl)
HR (1) HRP20121034T1 (pl)
MX (1) MX2009001788A (pl)
PL (1) PL2056807T3 (pl)
PT (1) PT2056807E (pl)
RU (1) RU2440110C2 (pl)
SI (1) SI2056807T1 (pl)
WO (1) WO2008021532A2 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2414205T3 (es) 2006-06-02 2013-07-18 The Ohio State University Research Foundation Agentes terapéuticos para el tratamiento de linfoma de células del manto
JP5216769B2 (ja) * 2006-08-17 2013-06-19 ザ・ユニバーシティ・オブ・シカゴ 炎症性疾患の処置
SI2307007T1 (sl) * 2008-07-23 2014-11-28 Novartis Ag Modulatorji sfingozin 1 fosfatnega receptorja in njihova uporaba za zdravljenje mišičnega vnetja
EP2326325B1 (en) * 2008-08-18 2014-11-12 Novartis AG Azetidine derivative for the treatment of peripheral neuropathies
EA019808B1 (ru) * 2008-08-18 2014-06-30 Новартис Аг Производные аминоспиртов, предназначенные для лечения демиелинизирующих периферических невропатий
EP2177521A1 (en) 2008-10-14 2010-04-21 Almirall, S.A. New 2-Amidothiadiazole Derivatives
EP2344446A4 (en) 2008-10-17 2012-04-04 Akaal Pharma Pty Ltd S1P RECEPTOR MODULATORS
CN102186845B (zh) 2008-10-17 2016-09-07 阿卡制药有限公司 S1p受体调节剂以及它们的用途
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
AU2010236655A1 (en) 2009-04-13 2011-11-17 The Ohio State University Research Foundation Protein phosphatase 2A-activating agents
EP2418948B1 (en) 2009-04-17 2013-09-04 The Ohio State University Research Foundation Antiadhesion agents
AU2010282948C1 (en) 2009-08-10 2017-03-02 Active Biotech, Ab Treatment of BDNF-related disorders using laquinimod
EP2305660A1 (en) 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
EP2343287A1 (en) 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
KR20160129093A (ko) * 2010-03-03 2016-11-08 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 루푸스 신장염의 치료
EP2366702A1 (en) 2010-03-18 2011-09-21 Almirall, S.A. New oxadiazole derivatives
EP2390252A1 (en) 2010-05-19 2011-11-30 Almirall, S.A. New pyrazole derivatives
US8309768B2 (en) 2010-11-29 2012-11-13 The Ohio State University Research Foundation FTY720-derived anticancer agents
HK1199820A1 (en) * 2011-10-12 2015-07-24 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
AR089862A1 (es) 2012-02-03 2014-09-24 Teva Pharma USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
EP2708898A1 (de) 2012-09-14 2014-03-19 Sterna Biologicals GmbH & Co. Kg Verfahren zur Diagnose eines molekularen Phänotyps eines an einer mit chronischen Entzündungen einhergehenden Erkrankung leidenden Patienten
HK1215210A1 (zh) 2012-11-07 2016-08-19 Teva Pharmaceutical Industries Ltd. 拉喹莫德胺盐
CA2901849A1 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
CN103992985A (zh) * 2014-05-09 2014-08-20 上海大学 神经鞘氨醇在中枢神经系统中的作用
CN112237575A (zh) * 2020-11-09 2021-01-19 杭州端丽生物技术有限公司 芬戈莫德在防治鞘脂紊乱引起的神经退行性疾病中的医药用途
CN112924432A (zh) * 2021-04-08 2021-06-08 济宁市第一人民医院 一种血液真菌感染检测试剂盒及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948820A (en) * 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
AU6051800A (en) * 1999-06-16 2001-01-02 University Of Iowa Research Foundation, The Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
CN102526079B (zh) * 2002-09-24 2014-06-18 诺华股份有限公司 治疗脱髓鞘疾病的鞘氨醇-1-磷酸受体激动剂
JP4861177B2 (ja) * 2003-09-12 2012-01-25 ニューロノバ エービー 神経系の障害の処置
JP5216769B2 (ja) * 2006-08-17 2013-06-19 ザ・ユニバーシティ・オブ・シカゴ 炎症性疾患の処置

Also Published As

Publication number Publication date
US20150335666A1 (en) 2015-11-26
CA2660880A1 (en) 2008-02-21
AU2007284337B2 (en) 2012-07-19
AU2007284337A1 (en) 2008-02-21
WO2008021532A2 (en) 2008-02-21
HRP20121034T1 (hr) 2013-01-31
JP2015221824A (ja) 2015-12-10
US9101576B2 (en) 2015-08-11
EP2392320A1 (en) 2011-12-07
JP5216769B2 (ja) 2013-06-19
RU2009109418A (ru) 2010-09-27
SI2056807T1 (sl) 2012-12-31
JP2010500995A (ja) 2010-01-14
EP2056807A2 (en) 2009-05-13
CN102526736A (zh) 2012-07-04
RU2440110C2 (ru) 2012-01-20
CA2660880C (en) 2015-10-13
WO2008021532A3 (en) 2008-05-29
US20100310547A1 (en) 2010-12-09
HK1131047A1 (en) 2010-01-15
JP2013144694A (ja) 2013-07-25
BRPI0715950A2 (pt) 2013-07-30
US20130017190A1 (en) 2013-01-17
CN101553216A (zh) 2009-10-07
CN101553216B (zh) 2012-03-21
MX2009001788A (es) 2009-09-23
PT2056807E (pt) 2012-12-21
ES2393631T3 (es) 2012-12-26
US9370497B2 (en) 2016-06-21
US8258150B2 (en) 2012-09-04
CN102526736B (zh) 2016-01-20
EP2056807B1 (en) 2012-09-26
DK2056807T3 (da) 2012-10-22

Similar Documents

Publication Publication Date Title
PL2056807T3 (pl) Leczenie chorób zakaźnych
ZA200707591B (en) Dihyrothienopyrimidines for the treatment of inflammatory diseases
IL200368A0 (en) Treatment of diseases characterized by inflammation
ZA200710598B (en) Treatment of inflammatory conditions
SI2044111T1 (sl) Ciljanje komplementa faktorja H za zdravljenje bolezni
EP2004204A4 (en) TREATMENT OF NEURODEGENERATIVE DISEASES
PT2056863T (pt) Tratamento de doenças oculares
ZA200905364B (en) Treatment of diseases characterized by inflammation
ZA200806808B (en) Treatment of stressed patients
GB0700972D0 (en) Treatment of inflammatory disease
IL200091A (en) Kittensan to treat infectious diseases of the nail
PL2380585T3 (pl) Sposoby leczenia chorób autoimmunologicznych
GB0720976D0 (en) Treatment of inflammatory disease
EP1981343A4 (en) TREATMENT OF INFLAMMATORY DISEASES WITH TRIAZOL COMPOUNDS
GB0610183D0 (en) Treatment of neurodegenerative diseases
GB0723100D0 (en) Treatment of HFnEF
GB0526394D0 (en) Treatment of inflammatory diseases
GB0622136D0 (en) Treatment of gastrointestinal diseases
GB0623740D0 (en) Treatment of disease
ZA200904660B (en) Treatment of IL-1-Beta related diseases
GB0622137D0 (en) Treatment of gastrointestinal diseases
GB0611417D0 (en) Treatment of cndaria intoxication
GB0819446D0 (en) Treatment of inflammatory disorders
IL194261A0 (en) S-alkylisothiouronium derivatives for the treatment of inflammatory diseases
GB0411302D0 (en) Treatment of inflammatory diseases